Sanofi's (SNY) Genzyme announces the publication of results from its studies of Lemtrada in...


Sanofi's (SNY) Genzyme announces the publication of results from its studies of Lemtrada in patients with relapsing-remitting multiple sclerosis, in the November 1 online issue of The Lancet. Results show the drug was significantly more effective at reducing annualized relapse rates than its active competitor Rebif, and more patients on Lemtrada were relapse-free at two years. In addition, accumulation of disability was significantly slowed, and patients experienced actual improvement in disability scores, suggesting a reversal of disability in some patients. Shares +0.7% AH.

From other sites
Comments (1)
  • Goeleven
    , contributor
    Comments (617) | Send Message
     
    I bought just in time some more sny stocks.
    1 Nov 2012, 07:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs